OCT is initiating a new ophthalmology trial

30 September 2008

OCT is glad to announce that the company is starting the trial in neovascular macular degeneration with 3 sites and 15 patients to be enrolled in Baltic States.

OCT Vision

“OCT vision is to be recognized by pharmaceutical and biotech companies as a leading provider of clinical trials in Russia, Ukraine, Bulgaria, Belarus, Latvia, Lithuania, Estonia, Poland and Czech Republic. OCT is able to support any requirements that clients may have in the region, ranging from one-off advice to full-study implementation and execution. We are determined and decisive in expanding our activity at this rapidly growing market”— Dmitry Sharov, General Manager of OCT.